Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Vaxxas Pty. Ltd.
Headquarters: Brisbane, Queensland, Australia
Website: http://www.vaxxas.com
Year Founded: 2011
Status: Private
BioCentury | Jun 6, 2023
Management Tracks
Jin promoted to CEO at Ensem
Plus: Pedranti named CEO at Visgenx, and updates from Altoida, Vaxxas, Variant, Immodulon and Google Ventures
BioCentury | Dec 6, 2022
Product Development
Dec. 5 Quick Takes: Nkarta reports 70% complete response
Plus: Verve falls on clinical hold and updates from J&J, Affinia, TherapeuticsMD, Biogen and more
BioCentury | Dec 1, 2022
Management Tracks
Lee to take the helm at SK Biopharmaceuticals
Plus: Amgen vet Tagari to join insitro as CSO, and updates from Haystack, Vaxxas, Akili and more
BioCentury | Apr 21, 2022
Management Tracks
Romanelli rejoins Merck to lead Human Health International
Plus: SIB’s Durinx joins VIB, and updates from Orion, American Cancer Society, Ambys and more
BioCentury | Apr 14, 2022
Management Tracks
Murphy resigns from MaxCyte
Plus AbbVie’s Severino becomes CEO-partner at Flagship, and updates from Ikena, Fusion, Nimbus and more
BioCentury | Oct 29, 2021
Discovery & Translation
Omics-based target identification in UK Biobank and COVID-19 cohorts
Plus: technologies from Harvard, Texas A&M, Disney lab and more
BioCentury | Jun 4, 2020
Product Development
June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more
BioCentury | Mar 20, 2020
Translation in Brief
Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar
BioCentury’s roundup of preclinical news
Items per page:
1 - 10 of 15